Figure legends
FIGURE 1. Clinical course of individual patients from the initiation of metronomic chemotherapy. The interpretations of lines or symbols are indicated in the figure. Abbreviations; Pt: patient, DS: disease status, BR: best response, MC: metronomic chemotherapy, CR: complete response, PR: partial response, SD: stable disease, PD progressive disease.
FIGURE 2 Survival curve of the patients after initiation of metronomic chemotherapy, except for 2 patients who received MC as a maintenance therapy. A: Overall survival curve; the overall survival rate was 56.3% at 12 months and 27.3% at 24 months. B: Progression free survival curve; the PFS rate was 14.3% at both 12 and 24 months. Abbreviations; MC: metronomic chemotherapy.
FIGURE 3. Overall survival curve by response to metronomic chemotherapy.
Panel A shows data of 16 patients; responders include patients with initially, partial remission, stable disease who keep disease status, and patients with progressive disease who achieved disease stabilization. The OS rate was 88.9% in responders and 14.3% in non-responders at 12 months; responders had longer survival times than non-responders (median 21 months vs. 5.2 months). Panel B shows the data of patients who started metronomic chemotherapy in progression disease status. The OS rate was 80% in responders and 16.7% in non-responders at 12 months; responders had longer survival times than non-responders (median 19.4 months vs. 4.7 months). Abbreviations; MC: metronomic chemotherapy, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease.
FIGURE 4 Incidence of febrile neutropenia per month during cytotoxic chemotherapy and metronomic chemotherapy. All patients, except for patient #14, indicated an apparently decreased number of episodes. Abbreviations; Pt: patient.